Best Pharmaceutical Stocks Canada

Pharmaceutical Stocks Canada

Creso is riding a wave of easing regulations on cannabis as the company also unveiled plans to expand into Canada’s largest recreational market. The Canadian biotech company, which is a leader in COVID-19 therapies, has seen its share price soar 185 per cent in the past year, with ARQ-531, which like ArQule is on the same level as CG-806, up by more than 10 per cent. News that pharmaceutical giant Merck would take over the company has doubled APS’s value in the last month and a half of this year. Sources: 0, 1, 9

At the time, all pharmaceutical stocks on the list had a cap, but the number of publicly traded biotechnology companies in Canada with a market cap of at least $1 billion rose 18%. Sources: 2, 3

Although there are few domestic pharmaceutical stocks to choose from, owning these stocks can provide Canadians with income and diversification. Alternatively, you can buy shares in biotechnology companies that are traded on the Canadian stock exchanges. Sources: 5, 7

It is also worth noting that Alexion has acquired and merged several companies since its inception, including Gilead Sciences (NASDAQ: GILD) and Merck & Co. Sources: 11

In 2009, Watson Pharmaceutical Inc., a top-selling generic drugmaker, acquired the Arnhem, N.J., facility, now called Pilar5 Pharma. Footnote: Similarly, BMS sold its plant to Uman Pharma in 2008, and Pfizer sold it to Keata Pharma of Korea for $1.5 billion in 2009. Valeant has also tried to acquire Actavis and Cephalon, but the biggest acquisition was the $2.2 billion acquisition of the US drugmaker’s assets. This is only the latest in a long line of global MNEs to acquire the pipeline of Canadian biopharma SMEs and is one of their largest acquisitions to date. Sources: 2, 10

The company is better known as a manufacturer of Tylenol and Band-Aid, but also has a large and profitable pharmaceutical division. The company, founded in Montevideo, Uruguay, in 1988, is an established pharmaceutical and medical device company developing medically registered and approved herbal cannabinoid products developed by Sandoz, one of the world’s largest manufacturers and distributors of cannabinoids and other cannabinoids. Sandoz produces the majority of injectable medicines used in Canada, as well as a wide range of medical and surgical products. Sources: 2, 5, 8

Overall, the Canadian pharmaceutical sector is the tenth largest in the world and accounts for 2 percent of the global market. Interestingly, Canada has the second largest market share among the seven countries in global pharmaceuticals, behind the United States. Sources: 3, 6

These companies are actively developing drugs to fight diseases, even coronavirus pandemics, and there are a number of biotech stocks listed on the Toronto Stock Exchange (TSX Venture Exchange) and the Canadian Securities Exchange. These returns are possible because pharmaceutical companies develop products that people need, medicines that treat or prevent diseases such as cancer, diabetes, heart disease, Alzheimer’s, Parkinson’s and Alzheimer’s, and invest constantly in research and development to bring new medicines to market. Sources: 11, 13

Canada has a number of pharmaceutical companies that have had great success in the past, and many of them are able to introduce new medicines for a wide range of diseases, including cancer, diabetes, heart disease, Parkinson’s and Alzheimer’s. Sources: 12

The Canadian pharmaceutical stocks listed below have been compiled using the TradingView stock screening device. This page provides a list of US listed pharmaceutical ETFs tracked by the ETF database. The following table shows all ETFs listed in the US pharmaceutical industry and currently tagged in our ETF database. There are currently no pharmaceutical theses traded in the US, which we mark with “ETF” in our database, but there are a number of them. Sources: 3, 4

Below, the Investing News Network has presented the top ten pharmaceutical stocks in Canada for their annual performance. Are you ready to see them in 2020, or even consider buying them? Sources: 3, 11

Canadian companies Pfizer and GlaxoSmithKline, which are based on the top 10 largest companies, are the two companies that have experienced negative growth since 2011. At the same time as the patent cliff was being raised, two generic drug companies were among the top 10 companies for the first time in 2007. Under J. Michael Pearson’s leadership, Valeant has pursued a strategy of buying other pharmaceutical companies that produce effective drugs for a variety of medical problems, and then raising the price of those drugs. Sources: 2, 10

Creso capitalised on the shift by revealing that its Canadian subsidiary Mernova Medicinal has branched out into Ontario, the largest recreational cannabis market in Canada. Chief executive Brendan Kennedy noted that Canada had to act to export medicinal cannabis as a biotech pharmaceutical product. Sources: 9, 12

The Canadian pharmaceutical market alone is sufficient to support and justify the full development costs of a pharmaceutical product. Clinical research in Canada generally accounts for only a small fraction of the total research and development costs of pharmaceutical products. In fact, only 5% of Creso’s annual research budget is used for clinical research, less than half of it for medicinal cannabis. Sources: 2

Cited Sources

Leave a Comment

Your email address will not be published. Required fields are marked *

Chinese (Simplified)EnglishFrenchSpanish

Join Our Facebook Community

Get access to daily picks, news and share in our active conversations!